Ildong Pharmaceutical said on the 14th it will expand the Asian rollout of its hyperlipidemia treatment DROPTOP. Hyperlipidemia is a condition of high blood cholesterol that can lead to cardiovascular diseases such as myocardial infarction and stroke.
The company signed an agreement with Indonesian drugmaker Kalbe Farma to enter three additional Association of Southeast Asian Nations (ASEAN) countries. Ildong Pharmaceutical signed a supply deal with Kalbe Farma in 2020 and has been introducing DROPTOP in Southeast Asia since 2023. With this additional agreement, the two sides have established a partnership in eight Southeast Asian countries.
DROPTOP is being sold locally under the name Rozet. In the three years since launch, it has recorded a 130% compound annual growth rate. An Ildong Pharmaceutical official said, "We plan to sequentially pursue product approvals and launch procedures in the countries covered by this agreement."